BR112022024294A2 - Bioconjugado shigella-tetravalente (shigella4v)". - Google Patents

Bioconjugado shigella-tetravalente (shigella4v)".

Info

Publication number
BR112022024294A2
BR112022024294A2 BR112022024294A BR112022024294A BR112022024294A2 BR 112022024294 A2 BR112022024294 A2 BR 112022024294A2 BR 112022024294 A BR112022024294 A BR 112022024294A BR 112022024294 A BR112022024294 A BR 112022024294A BR 112022024294 A2 BR112022024294 A2 BR 112022024294A2
Authority
BR
Brazil
Prior art keywords
shigella
shigella4v
bioconjugate
tetravalent
composition
Prior art date
Application number
BR112022024294A
Other languages
English (en)
Inventor
Edward Braun Martin
Follador Rainer
Jochen Kemmler Stefan
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of BR112022024294A2 publication Critical patent/BR112022024294A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0283—Shigella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/25—Shigella (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

BIOCONJUGADO SHIGELLATETRAVALENTE (SHIGELLA4V). A presente invenção refere-se a uma composição compre-endendo bioconjugados Shigella-Tetravalente (Shigella 4-valente). A referida composição engloba os antígenos O-polissacarídicos de Shi-gella dos sorotipos Shigella flexneri 2a, 3a, 6 e Shigella sonnei ligados covalentemente ao transportador de proteína.
BR112022024294A 2020-06-18 2021-06-17 Bioconjugado shigella-tetravalente (shigella4v)". BR112022024294A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063040844P 2020-06-18 2020-06-18
US202063043883P 2020-06-25 2020-06-25
EP20182138 2020-06-25
EP20182139 2020-06-25
PCT/IB2021/055361 WO2021255684A1 (en) 2020-06-18 2021-06-17 Shigella-tetravalent (shigella4v) bioconjugate

Publications (1)

Publication Number Publication Date
BR112022024294A2 true BR112022024294A2 (pt) 2023-02-28

Family

ID=76502778

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022024294A BR112022024294A2 (pt) 2020-06-18 2021-06-17 Bioconjugado shigella-tetravalente (shigella4v)".

Country Status (8)

Country Link
US (1) US20230346902A1 (pt)
EP (1) EP4168040A1 (pt)
JP (1) JP2023530154A (pt)
CN (1) CN115697396A (pt)
BR (1) BR112022024294A2 (pt)
CA (1) CA3185719A1 (pt)
MX (1) MX2022016587A (pt)
WO (1) WO2021255684A1 (pt)

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
WO2003074687A1 (en) 2002-03-07 2003-09-12 Eidgenössische Technische Hochschule Zürich System and method for the production of recombinant glycosylated proteins in a prokaryotic host
ES2703061T3 (es) 2005-05-11 2019-03-06 Eth Zuerich Proteínas N-glicosiladas recombinantes procedentes de células procariotas
ATE539079T1 (de) 2006-03-23 2012-01-15 Novartis Ag Imidazochinoxalinverbindungen als immunmodulatoren
US8063063B2 (en) 2006-03-23 2011-11-22 Novartis Ag Immunopotentiating compounds
US9238830B2 (en) 2006-12-13 2016-01-19 The Governors Of The University Of Alberta Methods and systems for O-glycosylating proteins
CA2716187C (en) 2008-02-20 2020-01-07 Glycovaxyn Ag Bioconjugates made from recombinant n-glycosylated proteins from procaryotic cells
AU2010322454B2 (en) 2009-11-19 2016-05-19 Glaxosmithkline Biologicals S.A. Biosynthetic system that produces immunogenic polysaccharides in prokaryotic cells
EP2906681B1 (en) * 2012-10-12 2019-01-09 GlaxoSmithKline Biologicals S.A. Methods of host cell modification
SG11201606889PA (en) 2014-02-24 2016-09-29 Glycovaxyn Ag Novel polysaccharide and uses thereof
EA035556B1 (ru) * 2014-07-25 2020-07-07 Биосинз С.Р.Л. Гликоконъюгатные вакцины, содержащие основные структурные единицы молекулярной конструкции, экспрессирующей встроенные множественные эпитопы, для составления вакцины широкого спектра действия против инфекций, вызываемых энтеропатогенными бактериями
CN105695497B (zh) 2014-11-27 2019-09-24 中国人民解放军军事医学科学院生物工程研究所 一种细菌多糖修饰的重组融合蛋白的制备方法及其应用
GB201518668D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Immunogenic Comosition

Also Published As

Publication number Publication date
WO2021255684A1 (en) 2021-12-23
MX2022016587A (es) 2023-02-01
EP4168040A1 (en) 2023-04-26
CN115697396A (zh) 2023-02-03
US20230346902A1 (en) 2023-11-02
JP2023530154A (ja) 2023-07-13
CA3185719A1 (en) 2021-12-23

Similar Documents

Publication Publication Date Title
EA202092899A1 (ru) Гетероарильные соединения для лечения болезни гентингтона
Wang et al. Protein change of intestinal epithelial cells induced in vitro by Trichinella spiralis infective larvae
CY1119376T1 (el) Αντισωματα ειδικα για τη μορφη πρωτοϊνιδιου της βητα-αμυλοειδους πρωτεϊνης
EA202191432A1 (ru) Агонисты glp-1r и их применения
EA202092001A1 (ru) Соединения для лечения болезни гентингтона
BR9915852A (pt) Conjugado de hapteno-portador para tratamento e prevenção do vìcio da nicotina
RU2017123262A (ru) Иммуногенные композиции для применения в пневмококковых вакцинах
Hoque et al. Oleic acid may be the key contributor in the BAMLET-induced erythrocyte hemolysis and tumoricidal action
BR0211926A (pt) agentes para realçar a resposta imune
Subramanian et al. Lysophospholipid sensing triggers secretion of flagellin from pathogenic salmonella
PE20110023A1 (es) Composiciones inmunogenicas de antigenos de staphylococcus aureus
BR112022000216A2 (pt) Anticorpos direcionados a dll3 e usos dos mesmos
DE602006017225D1 (de) Erbsenproteinzusammensetzung
BRPI0412671A (pt) conjugados de um polìmero e uma proteìna ligados por um grupo de ligação de oxima
Wang et al. Protein changes in Trichinella spiralis muscle larvae in vitro induced by bovine bile
CY1114716T1 (el) Ανασυσταθεντα επιφανειοδραστικα τα οποια διαθετουν βελτιωμενες ιδιοτητες
BR0113915A (pt) Uso de adenil ciclase da espécie bordetella, composição imunogênica ou farmacêutica, uso da mesma, e , vetor proteináceo
NO996514L (no) Overflateantigener og proteiner nyttige i sammensetninger for diagnose og forebygging av Lymesykdom
Chen et al. Zebrafish intelectin 1 (zITLN1) plays a role in the innate immune response
BR112022024294A2 (pt) Bioconjugado shigella-tetravalente (shigella4v)".
Khanifar et al. Prevention of EHEC infection by chitosan nano-structure coupled with synthetic recombinant antigen
Minnaard et al. Effect of Bacillus cereus exocellular factors on human intestinal epithelial cells
BRPI0504117A (pt) epìtopos, combinação de epìtopos, usos de epìtopos ou sua combinação, composição, usos da composição, vacinas profiláticas anti-hiv-1, vacinas terapêuticas, método para a identificação de epìtopos e métodos para o tratamento ou prevenção
BR112022003046A2 (pt) Conjugados de il-15 e usos dos mesmos
BR112023023671A2 (pt) Composições imunogênicas compreendendo antígenos de sacarídeo capsular conjugados e usos dos mesmos